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SUMMARY/ABSTRACT                                                                              
 
This paper describes some different investigations of phage therapy within veterinary medicine, 
in treating some of the most common bacterial infections in poultry, cattle and fish. As a red 
thread, phage therapy is being compared and contrasted with the current standard antibiotic 
treatment within some common diseases, as well as in general, in the discussion section.  
Bacteriophages, also known simply as phages, are bacterial (obligate) parasites or viruses that 
infect, replicate inside and eventually lyse their host bacterium, letting out hundreds of new 
phages. Since phages depend on bacteria as their host, they can be used for therapeutic purposes 
to help the immune system against the pathogens by killing the bacteria. 
Salmonellosis is caused by Salmonella bacteria and it is one of the most common and important 
infections transmitted between animals and man (zoonosis). Salmonella phages proved very 
effective in treating mice and chicken infected with Salmonella with a success rate of 90-100% 
(Lenev, 2013). 
Treatment of rabbits infected with Vibrio cholera by phages did not provide any successful 
results on the rabbit models, in contrast to the successful trial of treating cholera in humans. This 
is one of the examples how the effect of phage therapy application can vary within different 
species.  
Phages have shown to be effective against Enterococcus in mice models, with the pathogen’s 
significant decrease under infective dose; however, a tendency has been found that the earlier the 
treatment started the better result was obtained.  
When tested against Clostridium difficile, phages were able to protect the mice models from the 
disease but the effect did not endure for long. In all the different trials, it remains important to 
neutralise the gastric acid before administering phages orally, since low pH deactivates them.  
In the aquatic sphere, the two principle diseases have been taken up – aeromonosis and 
pseudomonosis, where phage therapy is still in the mode of trial, but already suggested by some 
researchers (Kafydova and Grinyova, 2014) to be used for treatment. Phage therapy has shown 
significant effects on Pseudomonas pleoglossicida, and a very promising result has been 
demonstrated on the Lactococcus bacteria, with maximal success and absolute protection of fish 
against the pathogen.    
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SAMMANFATTNING 
Denna uppsats beskriver några olika undersökningar av fagbehandling inom veterinärmedicin, 
inom några av de vanligaste bakterieinfektionerna hos fjäderfä, boskap och fisk. Som en röd tråd 
jämförs fagterapi med den aktuella antibiotikabehandlingen inom några vanliga sjukdomar samt 
allmänt i diskussionsdelen. 
 
Bakteriofager, även kända som fager, är bakteriella (obligata) parasiter eller virus som infekterar, 
replikerar inuti och så småningom lyserar deras bakterievärdar och släpper ut hundratals nya 
fager. Eftersom fager är beroende av bakterier som värdar, kan de användas för terapeutiska 
ändamål för att hjälpa immunsystemet mot patogenerna, genom att avdöda bakterierna. 
 
Salmonellos orsakas av Salmonella-bakterier och det är en av de vanligaste och viktigaste 
infektionerna mellan djur och människor (zoonos). Salmonellafager visade sig vara mycket 
effektiva vid behandling av möss och kaniner, infekterade med salmonella, med en 
framgångsgrad på 90-100% (Lenev, 2013). 
 
Fagbehandling av kaniner infekterade med Vibrio cholera gav inga framgångsrika resultat på 
kaninmodellerna, i motsats till det framgångsrika försöket att behandla kolera hos människor. 
Detta är ett exempel på hur fagbehandlingseffekt kan variera inom olika arter. 
 
Fager har visat sig vara effektiva mot Enterococcus i mössmodeller, med patogenens signifikanta 
minskning under infektionsdos; emellertid, har man hittad en tendens: ju tidigare behandlingen 
började, desto bättre resultat erhölls. 
 
När fager testades mot Clostridium difficile, kunde fager skydda musmodellerna från sjukdomen, 
men effekten varade inte länge. I de olika försöken är det viktigt att neutralisera magsyran före 
administrering av fager oralt, eftersom lågt pH deaktiverar dem. 
 
I akvatiska världen har de två principiella sjukdomarna upptagits - aeromonos och pseudomonos, 
där fagbehandling fortfarande är i provtillståndet, men som redan föreslagits av vissa forskare 
(Kafydova och Grinyova, 2014) som en alternativ behandling. Fagterapi har visat signifikanta 
effekter på Pseudomonas pleoglossicida, och ett mycket lovande resultat har visats på 
Lactococcus-bakterierna, med maximal framgång och absolut skydd av fisk mot patogenen. 
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INTRODUCTION 
Antibiotic resistance has been an alarming issue in the recent decades, subject to much discussion 
within the humane medical sphere, as well as in veterinary medicine. The ongoing debate 
exposes the fact that bacterial strains continually develop resistance towards the existing 
antibiotics by the means of adaptive mutations, and that new types of antibiotics are not 
introduced (Golkar et al., 2014). By trying to find a solution for this problem, acceptable 
alternatives to antibiotics have to be found, e.g. an antibacterial agent that would be able to 
surpass this constant bacterial resistance development, for example bacteriophages.  
Phage therapy has been known since the end of 19th century, but with the discovery and rise of 
antibiotics, the interest in bacteriophages faded away in some countries. However, in recent 
decades an interest in phage therapy has returned, this time viewed from another perspective.  
This literature review aims to elucidate the application of phage therapy in veterinary medicine, 
considering its advantages and disadvantages. This paper takes up certain bacterial diseases of 
some of the most common animal species in relation to phage therapy. A general overview of the 
current condition of antibiotic treatment of these pathologies has also been discussed. Moreover, 
phage therapy is to be evaluated as a potential future compliment or even alternative to 
antibiotics, at least considering the mentioned diseases within veterinary medicine.  
 
MATERIAL AND METHODS 
Literature, in this study, has been found using, Pubmed, and other scientific databases. The focus 
was placed on the international origin of the sources and their specificity in bacteriophageal 
research. Such search terms as "bacteriophages", "phage therapy", "phage treatment of aquatic 
organisms" have been used. 
 
LITERATURE REVIEW 
 
BACTERIOPHAGEAL BIOLOGY 
Bacteriophages (etymology: “bacteria” and greek “phagos” – consuming) can be viewed as 
obligate parasites for bacteria. These viruses received this functional name, since they invade 
bacteria and “consume” their cells, replicate within them and leave the cell with all their copied 
“progeny” usually by lysing the bacteria. Bacteriophages (sometimes abbreviated to “phages”) 
can be found in many different environments, such as soil, water, glacier, etc. The important 
condition being that bacteria also be found there, since phages cannot live without bacterial hosts. 
It has been noticed that phages effectively infect enteric bacteria, such as E. coli, Shigella, 
Salmonella typhimurium, etc. Bacteriophages are unique microorganisms, they are also known as 
“good viruses”, their survival dependence on bacteria, which are sensitive to phages, including 
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even most pathogenic and virulent strains thereof, gives rise to a distinctive treatment technique 
known as phage therapy (Efremova and Nikolaeva, 2013) (Sherbenkov, 2013).  
Being a virus, a phage has a viral structure: genetic material (single or double stranded RNA or 
DNA), surrounded by a capsid (protein coat). Its size ranges approximately from 20 nm to 200 
nm (up to 800 nm long within the filiform) (Tets et al., 2002). Larger size phages are usually 
constructed as icosahedrons with spiral symmetry tail. Phages are more resistant to both physical 
and chemical influence than bacteria; for example, they can endure pH ranging from 5 to 8, 
neither are they deactivated by ethanol, phenol, cyanide or chloroform. However, boiling, acids, 
formalin and UV-light, can destroy them. (Bykov et al., 1998)  
The potential magnitude of phage therapy effect can be imagined if one considers how phages 
replicate. It is similar to how any virus replicates: the viral genome enters the cell and the genetic 
information within the virus redirects the cell to produce many new copies of the virus. 
Subsequently, the phages are released from the lysed bacterial cell and the newly formed phages 
can infect a multitude of other bacteria in the vicinity. All this provides phages with an 
extraordinary bactericidal potential, rendering them to be powerful therapeutic agents against 
bacterial diseases (Sulakvelidze and Kutter, 2012) 
 
                                                                                                              
                                                                                                                                     
BACTERIOPHAGEAL CLASSIFICATION 
Today bacteriophages are usually classified into 13 families, over 140 genii, more than 5300 
types of phages. They can be distinguished by shape, structure, nucleic acid and by its interaction 
with microbial host. Phages are also distinguished by size: small, medium, large; shape: filiform, 
spherical; phages with and without head and/or tail, etc.  
Furthermore, phages can be differentiated into virulent (productive infection, where the phage 
replicates in the cell and leaves it afterwards) and temperate (reductive infection, where the phage 
integrates its genome into the cell, becoming a prophage and rendering the cell lysogenous). The 
lysogenous cell carries the genes of the prophage, which can anytime leave the bacterial 
chromosome and start replicating and then its progeny leave the cell by lysing it (Bykov et al., 
1998) (Korotyayev and Babichev, 2002). 
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MOLECULAR MECHANISMS OF PHAGE THERAPY 
After having penetrated the bacterial cell, the phage inserts its genetic material into the cell to 
replicate it, in order to produce up to 300 new phage particles, whose complete lytic cycle (from 
the moment of absorption into the cell to its exit in cellular lysis) lasts for 30-40 min. (Marina, 
2011). Lysosyme from the phages dissolves the bacterial cell wall, thus letting the phage virions 
leave the microbe, in order for them to further infect and lyse other phage sensitive bacteria. 
Thus, in a very short time, a single phage can multiply to produce millions of phages, all with the 
potential to kill bacteria and further subsequent magnification of phage shall then occur. 
Nevertheless, phages are self-limiting, that is when no target bacteria is around no replication 
occurs and the phages will eventually denaturise and disintegrate.  
The phages vary in specificity, being type-specific (lysing certain types of bacteria within one 
species), monovalent (lysing bacteria of only one species) and polyvalent (lysing bacteria of 
different species within a genus). Virulent phages are lytic, implying that they lyse the cell upon 
replication and formation of new phages, whereas temperate phages are lysogenic, meaning that 
they hijack the bacterial genome and force it to produce their viral proteins.   
Transduction is a process of gene transportation between bacteria, carried out by phages. One big 
concern in using phages in therapy is the risk of spreading virulence genes between bacteria. 
Temperate phages can integrate into the bacterial chromosome and sometimes they can take with 
them genes close to their integration site. By this mechanism, many temperate phages carry 
virulence genes in their genome, e.g. the Shiga toxin carrying phages causing E. coli to become 
the feared STEC strains, triggering very severe food poisonings (Martinez-Castillo and Muniesa, 
2014). Thus, it is important to use only virulent phages in phage therapy. 
 
PHAGE THERAPY IN VETERINARY MEDICINE 
Phage therapy has been used in veterinary science since the beginning of the 20th century. In 
1919 phages were first used in France against bird typhoid fever. Salmonella gallinarum, as well 
as their bacteriophages, were isolated from the infected chicken and when tested, phages proved 
to be effective against Salmonella gallinarum. The first trial model for testing phage therapy was 
mice salmonellosis, mainly caused by Salmonella typhimurium. Phages were both administered 
intraperitoneally and orally, where the latter did not give a positive bactericidal result and the 
former only decreased microbial spread insignificantly (Topley, et al., 1925). This trial failed 
most probably because the right type of phage was not used, since later scientists managed to 
infect typhoid bacteria in vitro successfully with a well-chosen anti-tiphoid phage (Fisk, et al., 
1938). Many subsequent experiments in treating rabbits, Guinee pigs, mice and rats, infected 
with streptococci and staphylococci have not shown to be effective (Compton, 1930). 
Nevertheless, there are multiple evidence of successful phage treatment of streptococcal 
meningitis in rabbits (Kolmer and Rule, 1933) (Eaton & Bayne-Jones , 1934) E.coli cystitis in 
rabbits and Guinee pigs (Larkum, 1926), Salmonella dysenteriae encephalitis in mice (Dubos, et 
al., 1943) (Sulakvelidze and Kutter, 2012). 
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Today phages are used in both human and veterinary medicine. Among their advantageous 
characteristics, such as their specificity on bacteria, qualifies them for use in phage therapy. 
Modern phage medicine is based upon virulent phages of a broad range of action that are active 
against antibiotic resistant bacteria. The latter phenomenon (antibiotic resistance development) 
has in recent decades led to less efficient bacterial disease treatment, as well as to an increase of 
persistent infections and latency (Pimenov, et. al., 2006). Antibiotics usage today is narrowed 
down as much as possible, in order to avoid, or at least, decelerate resistance growth, which 
provides more importance of the ecologically safe phage therapy as a modern anti-epizootic 
treatment, which is to be opted for (Lenev, 1992) (Sulakvelidze and Kutter, 2012).  
 
 
SALMONELLA IN POULTRY 
Salmonella remains to be a large problem for both human and veterinary medicine. WHO 
classifies Salmonellosis as epidemiologically the most severe zoonosis to eradicate, especially 
considering the fact of intense antibiotic resistance development (Pimenov, et. al., 2005). Poultry 
farms are the primary source of salmonella dispersion. Salmonellosis of all serovars contributes 
with a severe socioeconomic damage (Kaftyreva et al., 2008). Phages have exceptional 
possibilities, since they can be used in the different parts of the food chain, from such 
prophylactic means as sanitation in farms to treating carcasses in the slaughterhouse (Lenev, 
1992). Phages that are used against Salmonella typhimurium are typically isolated from bird 
faeces in poultry farms and dovecotes. Salmonella typhimurium phage (type B1 Siphoviridae) 
isolates have shown maximal lytic activity against Salmonella enterica (Pimenov, 2013). 
Salmonella enteritidis is the dominant salmonella strain for both chicken and humans (Kuzmin, 
1995) (Michael, 2010). It has been shown in an experiment on salmonella infected mice and 
rabbits that 90-100% of the animals were saved from death, as compared to 0-10% in the control 
group (Lenev, 2013). Thereafter, these phages were successfully used in poultry farms, dovecotes 
and zoos. In conclusion, the typhimurium phage and the bivalent salmonella phage are 
successfully introduced into veterinary praxis and are recommended to veterinary specialists, 
thereby proving to be promising anti-epizootic medicals (Pleshakova and Stepanov, 2013). In 
another phage therapy experiment in broiler poultry, from the pathologic material from broiler 
chicken, 11 Salmonella enteritidis strains have been isolated in the first day, and on day 29, no 
strains were detected, while the control group had all the 11 strains for 32 days. In addition, 
average daily body mass gain in the experimental group was 0.7 g/chicken higher than in the 
control group, and the productivity index was 9.4 times the index of the control group. As a 
result, it can be concluded that phage therapy eradicates salmonella, increases average daily mass 
gain, as well as the final mass at slaughter together with the productivity index (Pleshakova and 
Stepanov, 2013). 
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 ESCHERICHIA COLI INFECTIONS IN BOVINE CATTLE AND SWINE  
Bacteriophages are known for being effective against Enterobacteriaceae in general and E. coli 
in specific (Huff, et al., 2003). An experiment has been done on escherichiosis in piglets, where 
T4 phage from the Myoviridae family was used (minimum of 105 phages/g body mass were 
applied) providing with up to 100% protection, in all dosages; the optimal dosage has been 
determined to be triple treatment with 109 phages/1-month old piglets (Skoblikow and Zimin, 
2013). 
Experiments have been set on calves and lambs, orally infected by 3x109 E. coli type 
O9:K30.99.57 and none of the 9 phage treated calves, with the dosage of 1011 phages, got 
diseased, as compared to the control group, where 93% died. While the phages were unable to 
eradicate the E. coli completely, it could decrease the amount of bacteria to a level below the 
pathogenic threshold; almost no phagoresistant mutated E. coli have been determined (Smith and 
Huggins, 1983).    
Investigations have also shown that the low pH of the gastric acid had to be neutralised, in order 
to preserve the phages given orally, which could easily be done by sodium bicarbonate (given 
prior to phage therapy) or milk (Smith and Huggins, 1983).  
In yet another experiment, calves were orally infected by 1010 K1+ E. coli within 2 hours after 
delivery, which caused a severe septic reaction within the next 18-36 hours; thereafter, they were 
obviously euthanized; however, 3 out of 4 infected calves in the phage-treated group remained 
healthy after 8 hours and the 4th one was only slightly sick. R-phages (1010 PFU) were inoculated 
intramuscularly 8 hours after the oral inoculation with bacteria into the thigh (Barrow et al., 
1998).  
 
VIBRIO CHOLERAE IN RABBITS 
In an experiement, 10 V. cholerae phages (B1 – B10) were tested (1010 – 1011 phages/ml) against 
V. cholerae using an in vivo rabbit model. They were injected together with 108 CFU ATCC 
51352 V. cholerae into the rabbit intestines; however, neither prophylactic nor therapeutic effect 
has been noticed, in contrast to the successful human cholera phage treatment, subsequently taken 
up and discussed by Summers, 1999. Researchers surmise that this could have occurred since 
certain components in the rabbit intestines inhibit phage activity (Sarkar et al., 1996) 
(Sulakvelidze and Kutter, 2012).  
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ENTEROCOCCUS FAECIUM IN MICE   
Phage therapy was tested against vancomycin-resistant Enterococcus on mice models, by 
infecting the mice with 109 CFU Enterococcous faecium. A single intraperitoneal injection 45 
min after bacterial infection of 3x109 phages protected all the mice, whereas when the treatment 
was postponed until disease peaked (18-24 hours after infecting), only 50% could be saved from 
death. In both cases, the amount of pathogen has significantly decreased in the blood (Biswas et 
al., 2002) (Sulakvelidze and Kutter, 2012). 
 
 
CLOSTRIUDIUM DIFFICILE IN HAMSTERS 
Phages were extracted and isolated from lysogenous C. difficile to be tested on 26 hamsters, who 
were gastrically infected by 1 ml 103 CFU/ml C. difficile. The phage-treated group received 1 ml 
108 phages directly, and additional phage doses were administered after each 8 hours in two of 
the groups. All animals in the control group died within 96 hours after being infected, whereas all 
the hamsters in the treated group, except for one individual, survived the infection, although 
phages were not noted to have a prolonged effect. It has been concluded that phage therapy can 
be effective against pathogenic C. difficile, but it remains important to neutralise gastric acid 
when administering phages orally, in order for them not to get deactivated (Ramesh et al., 1999) 
(Sulakvelidze, 2012).  
 
 
PHAGE THERAPY IN AQUACULTURES  
Aquatic organisms are also prone to many bacterial diseases, such as aeromonosis and 
pseudomonosis, thus requiring antibiotic treatment, to escape economically harmful effect 
(increased mortality, decreased growth, etc.) on aquatic farms. Considering the problem of the 
progressively growing antibiotic resistance within bacteria, phage therapy can therefore find its 
application even here (Nasibullin et al., 2013).  
Aeromonas bacteria are a common pathogen within aquatics, causing aeromonosis, which is a 
dangerous disease encountered in aquacultures. Since many bacterial strains from the Aeromonas 
family can give rise to aeromonosis, its treatment is not easy to issue. (Nasibullin et al., 2013).  
Today the standard treatment against aeromonosis is usually antibiotics, iodine-containing 
compounds and formalin (Revenko, 1978); however, these treatment agents are not safe for the 
fish by inhibiting their intestinal microflora, exerting a hepatotoxic and nephrotoxic effects, as 
well as killing the saprophytes that are so important for the ecology. Gradually, bacteria develop 
antibiotic resistance via multiple mutations. Phage therapy can be used for treating aeromonosis. 
Among the advantages of phage therapy towards standard treatment, it can be noted that phages 
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are not toxic to the animal (e.g. immune system does not get inhibited and the bacterial flora is 
not damaged) and the phages are only active against one specific pathogen time (high 
specificity), no other microbes. Therefore, phage therapy has clear advantage in being used for 
treatment of aeromonosis.   
Another notable aquatic bacteria is Flavobacterium psychrophilum, a thin filiform gram-negative 
bacteria, causing BCWD (bacterial coldwater disease), also known as RTFS (rainbow trout fry 
syndrome), which is spread worldwide. Possessing three serotypes, this microbe has proved to be 
epizootic for fish exposed for stress, with mortality varying from 1-90%. It has been established 
that F. psychrophilum can both be transferred vertically and horizontally, where the vertical 
transfer occurs via roe infection, which makes it crucial to test both the spawner and the fertilised 
roe for the bacteria, before incubating it (Iida and Mizokami, 1996) (Nyman and Wiklund et al., 
2000) (Dzuba, 2012).  
The standard treatment is comprised of antibiotics; however, the problem of antibiotic resistance, 
mainly due to the development of a protective biofilm, is growing in relevance.  The bacterium 
still remains sensitive to tetracycline and erythromycin, somewhat less sensitive to oxolinic acid, 
and even less so to gentamycin and streptomycin, whereas all bacteria strands appeared to be 
resistant towards kanamycin. (Sundell and Wiklund, 2011) (Ustimenko, 2012). There is ongoing 
research on how phage therapy can be used for the treatment of RTFS. (Zolotukhin et al., 2013) 
Yet another fish disease to consider is pseudomonosis, characterised by such symptoms as 
fatigue, haemorages on gills and fins, dislocation of the scales, exophthalmos, etc., causing 
significant harm to aquacultures (Nasibullin et al., 2013) (Grinyova et al., 2013). Antibiotics are 
currently used against Pseudomonas. Phage therapy, being highly specific towards the microbe, 
with its lytic activity, is suggested as a means for treatment of pseudomonosis, (Vasilev et al., 
2013).  
Phage therapy has been shown to work on Lactococcus garvieae, by intraperitoneally infecting 
sea king fish fry and, thereupon, injecting L. garviae phages i.p. As a result, 100% of the fishes 
that undergone phage therapy survived, whereas only 10% of the fishes in the control group 
survived. (Nakai et al., 1999)  
Pseudomonas plecoglossicida is yet another opportunistic aquatic pathogen, inter alia, causing 
haemorragic ascites in fish. In a Japanese 2-week investigation, fish were infected orally with P. 
plecoglossicida (107 CFU/g) and thereupon fed with respective phages (107 BFU/g). After the 
first week the fishes in the control groups started to die, eventually rendering 65% mortality, 
whereas in the phage treated groups mortality did not exceed 23%. Laboratory experiments were 
neatly confirmed by a natural treatment session of P. plecoglossicida in a pond, which decreased 
the daily mortality rate to 5%, making it three times less after 14 days, as compared to the control 
groups (Sulakvelidze and Kutter, 2012).      
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DISCUSSION                                                                                                                
Today, phages regain their usage within human and veterinary medicine and new medicals are 
being created based on phages. They are usually compared to antibiotics, since both are the main 
treatment agents against bacterial diseases. Their efficiency is expressed in several aspects, such 
as their compatibility with other pharmaceuticals, their natural origin, and the fact that they are 
not known to cause allergies or addiction (Sulakvelidze et al., 2001).  
There are no known serious counter-indications and side effects when using phages, as compared 
to the multiple side effects, allergies, and secondary infections caused by antibiotic treatment 
(Yao and Moellering, 1995). Furthermore, an evident advantage is their positive effect against 
antibiotic-resistant bacteria, implying that even though phage-resistant bacteria come about, 
being resistant to a certain phage; they remain susceptible to other phages within the target range, 
as compared to antibiotics, where resistance to antibiotics is not limited to targeted bacteria. As 
some authors point out, possessing a broad-spectrum activity results in selection for many 
resistant bacterial species, not just for resistant mutants of the targeted bacteria (Salyers and 
Amabile-Cuevas, 1997); phages having a narrow-spectrum activity specifically select for 
resistant mutants of the targeted microbe, not selecting for resistance in other species. Phages are 
biotic viruses and their natural origin leads to the hypothesis that phages can potentially be 
selected against every antibiotic-resistant or phage-resistant bacterium by their ongoing adaptive 
capacity. In other words, viruses, being microorganisms, can always overcome the resistance that 
bacteria develop against them, constantly “manufacturing a newer key to the new lock”. In 
addition, their high specificity is beneficial, implying that a phage infects and thereby kills only a 
certain bacterial species, no other microorganisms, as compared to antibiotics that target both 
pathogens and normal microflora. This results in microbial disequilibrium and dysbacteriosis, 
which may lead to serious secondary infections, which do not develop after phage therapy 
(Chernomordik, 1989). Moreover, phages replicate at the site of infection, thus being abundantly 
available where needed, requiring less frequent phage administration for optimal therapeutic 
effect, as compared to antibiotics, which get metabolised and eliminated from the body and do 
not necessarily concentrate at the site of infection, unless being tropic to the respective tissue 
(Smith and Huggins, 1982).  
However, phages are also known to have their respective limitations. As mentioned above, 
phages are highly specific bactericidal agents, which can both be an advantage, namely that 
phages only target certain bacterial species, not killing unwanted microbes, yet simultaneously it 
is a disadvantage. It is known that bacterial strains of the same species may structurally differ 
within the species; due to this morphic variety, phages does not always succeed targeting bacteria 
within the same species.  
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Another important consequence of the phages’ high specificity is that the bacterial species must 
be identified prior to initiating phage therapy, as compared to antibiotics that are generally more 
effective than phages, when the identity of the etiologic pathogen is not yet known. Antibiotics 
simultaneously affect many bacterial strains; however, at the same time bacteria are more prone 
to develop resistance against them. Some authors reported certain side effects for therapeutic 
phages in vivo, which they surmise might have been evoked by the liberation of endotoxins from 
lysed bacteria (Cislo et al., 1987) (Slopek et al., 1987), also because these side effects are 
common for antibiotic therapy as well (Prins et al., 1994) (Sulakvelidze et al., 2001). 
Additionally, phages have not currently been discovered for all the known pathogenic bacteria, 
implying that phage therapy cannot access treating diseases caused by those bacterial species, 
without the respective phage against them. Specialised transduction, which has previously been 
described in this paper, is another difficulty that can disturb phage therapy. Finally, the host’s 
immunity can pose a potential threat to phages, recognising them as foreign, but phages usually 
operate fast and manage to infect bacteria, escaping the immunity.  
Considering both the strong and the weak sides of phages, as compared to antibiotics, in some 
countries phages are viewed as a secondary choice in humane medicine, to be used in cases 
where the stage is not acute and the condition is not death-threatening, or to be used as additives 
to the principal antibacterial (usually antibiotic) therapy. In the future, bacteriophages are most 
probably going to be a compliment to antibiotics, perhaps even used in synergy with them, due to 
the progressively increasing antibiotic resistance problem that is overwhelming. The following 
table is from a website and the activity of the functional range of these medicals cannot be 
validated. The phage medicals in this table can be purchased e.g. on this Russian website: 
https://www.medsovet.info/     
 
Bacteria Phage therapy 
Staphylococcus Staphage, pyophage, intestiphage 
Streptococcus Streptophage (liquid), pyopolyphage (tablets)  
E. coli Polyvalent pyophage, coliproteal phage 
Enterococcus Intestiphage 
Pseudomonas aeruginosa Pseudomonas aeruginosa phage (liquid) 
Klebsiella pneumoniae Polyvalent pyophage (liquid, purified) 
Proteus vulgaris et mirabilis Proteal phage (liquid), pyopolyphage (tablets) 
Figure 1. Prescribed phage therapy against some common bacterial infections 
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